Article
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Transplantation - 1 Apr 2015
Papadopoulos-Köhn Angela, Achterfeld Anne, Paul Andreas, Canbay Ali, Timm Jörg, Jochum Christoph, Gerken Guido, Herzer Kerstin
Abstract excerpt
BACKGROUND: Graft loss because of hepatitis C virus recurrence is a serious problem after liver transplantation (LT), and the response to pegylated interferon (PEG-IFN) and ribavirin (RBV) is poor. The significantly better response rates achieved with telaprevir (TVR)-based triple therapy have led to better graft and patient survival rates, but severe drug interactions may limit the usefulness of this therapy for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.